Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Drug

Ascletis ASC40 Phase III Success in Acne Vulgaris

Fineline Cube Jan 30, 2026
Company Drug

TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases

Fineline Cube Jan 30, 2026
Policy / Regulatory

China Unveils “Healthcare Foundation Strengthening Plan” to Bring Clinics Within 15‑Minute Reach

Fineline Cube Sep 11, 2025

The State Council released the Implementation Plan for the Healthcare Foundation Strengthening Project, setting a...

Company Drug

TransThera Sciences Secures China Phase II Trial Approval for Tinengotinib‑Fulvestrant Combination

Fineline Cube Sep 11, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced that the China National Medical Products Administration has...

Company Deals

Innovent Biologics & Cowell Health Forge Strategic Alliance to Boost Drug Access

Fineline Cube Sep 11, 2025

Innovent Biologics Inc. (HKG: 1801) announced a strategic cooperation agreement with Cowell Health. The partnership is...

Company Drug

Taiji Group Secures NMPA Approval to Begin Clinical Trials of Semaglutide Biosimilar

Fineline Cube Sep 11, 2025

China‑based Chongqing Taiji Industry (Group) Co., Ltd. (Taiji Group, SHA: 600129) announced that its semaglutide...

Company Drug

Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors

Fineline Cube Sep 11, 2025

China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...

Company Deals

Qilu Pharmaceutical & FDSTC Announce Strategic Partnership to Boost China’s Biomedical Innovation

Fineline Cube Sep 10, 2025

China‑based Qilu Pharmaceutical and the Foundation for the Development of Science and Technology in China (FDSTC),...

Company Deals

Corxel and WuXi Forge Cardiovascular Partnership to Accelerate Drug Development

Fineline Cube Sep 10, 2025

China‑based Corxel Pharmaceuticals (CORXEL) and WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), have...

Company Deals Medical Device

Danaher Partners with Beckman to Advance Alzheimer’s Blood‑Biomarker Diagnosis

Fineline Cube Sep 10, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced that its operating subsidiary,...

Company Drug Medical Device

Johnson & Johnson Secures FDA Approval for INLEXZO, a Ground‑breaking Intravesical System for Bladder Cancer

Fineline Cube Sep 10, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug...

Others

China’s 11th National Drug VBP Draft Unveils Major Pricing & Competition Reforms

Fineline Cube Sep 10, 2025

The second‑draft rules for China’s 11th round of national centralized drug procurement (VBP 11th) have...

Company Deals Drug

Kexing Biopharm Secures Global Rights to Humanwell PuraCap’s Nintedanib

Fineline Cube Sep 10, 2025

China‑listed Kexing Biopharm Co., Ltd. (SHA: 688136) announced today a strategic commercialization agreement with Humanwell...

Company

Novo Nordisk Launches Company‑Wide Transformation to Drive Diabetes and Obesity Growth

Fineline Cube Sep 10, 2025

Danish diabetes and obesity leader Novo Nordisk A/S (NYSE: NVO) announced a sweeping organisational overhaul...

Company Deals

IASO Biotherapeutics & Cellbri Sign Global Cell‑Therapy Alliance

Fineline Cube Sep 10, 2025

China‑based IASO Biotherapeutics and Shenzhen Cellbri Bio‑Innovation Technology Co., Ltd. announced a global strategic cooperation...

Company Drug

Qilu Pharmaceutical Commences Phase III Trial of QLS31905 for Advanced Pancreatic Cancer

Fineline Cube Sep 10, 2025

China‑based Qilu Pharmaceutical Co., Ltd. announced that it has opened enrollment for its first‑in‑class QLS31905...

Company Drug

Novartis Expands Iptacopan Approval to IgA Nephropathy in China

Fineline Cube Sep 10, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first‑in‑class oral inhibitor Iptacopan (Fabhalta) has...

Company Drug

Sihuan Pharma Secures IND for Dual‑Target GLP‑1/GCGR Drug P052 Injection

Fineline Cube Sep 9, 2025

China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) announced that the Investigational New Drug (IND)...

Company Drug

Simcere Secures NMPA Approval for CDH17‑Targeting ADC SIM0609 in Advanced Solid Tumors

Fineline Cube Sep 9, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its internally developed SIM0609, a CDH17 antibody‑drug...

Company Medical Device

DaAn Gene Secures NMPA Approval for First HIVDNA Diagnostic Kit

Fineline Cube Sep 9, 2025

China‑based DaAn Gene Co., Ltd. (SHE: 002030), a research arm of Sun Yat‑sen University, announced that...

Policy / Regulatory

NMPA Releases Online Prescription Compliance Guidelines to Tighten Drug Retail Oversight

Fineline Cube Sep 9, 2025

The National Medical Products Administration (NMPA) issued a draft of its Compliance Guidelines for Online...

Company Deals

Sirnaomics Secures HK$138 M Investment from Bloomage Biotech, Expanding Oncology and Aesthetic Pipelines

Fineline Cube Sep 9, 2025

Sirnaomics Ltd. (HKG: 2257) announced a strategic investment agreement with Bloomage Biotech (Hong Kong) Limited, a...

Posts pagination

1 … 55 56 57 … 616

Recent updates

  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
  • Thermo Fisher Reports Q4 Revenue Growth on AI Innovation
  • TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases
  • Takeda Q3 Revenue Drops 3.3% on VYVANSE Generics, Raises Full-Year Forecast
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Drug

Ascletis ASC40 Phase III Success in Acne Vulgaris

Company

Thermo Fisher Reports Q4 Revenue Growth on AI Innovation

Company Drug

TYK Medicines Asandeutertinib Gets China Priority Review for NSCLC Brain Metastases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.